18-Methoxycoronaridine

18-Methoxycoronaridine
	File:18-methoxycoronaridine2.png
Identifiers
	IUPAC name (-)-18-methoxycoronaridine;
CAS Number	266686-77-5;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H28N2O3
Molar mass	368.50 g/mol

Overview

(-)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine and nicotine.^[1] 18MC is a selective α₃β₄ nicotinic antagonist and, opposed to ibogaine, has no affinity at the α₄β₂ subtype nor at NMDA-channels nor at the serotonin transporter.^[2] There is no publication that would indicate that it had ever been tested in humans.

↑ S.D. Glick (1996). "18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats". Brain Res. 719 (1–2): 29–35. PMID 8782860. line feed character in |title= at position 61 (help)
↑ I.M. Maisonneuve (2003). "Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment". Pharmacol. Biochem. Behav. 75 (3): 607–18. PMID 12895678.

Identifiers
File:18-methoxycoronaridine2.png
IUPAC name (-)-18-methoxycoronaridine
CAS Number	266686-77-5
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₂H₂₈N₂O₃
Molar mass	368.50 g/mol